Should I buy or sell Tarsus Pharmaceuticals stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tarsus Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TARS shares. View TARS analyst ratings or view top-rated stocks .

What is Tarsus Pharmaceuticals' stock price target for 2024?

8 Wall Street analysts have issued 1 year price objectives for Tarsus Pharmaceuticals' stock. Their TARS share price targets range from $30.00 to $59.00. On average, they anticipate the company's share price to reach $48.38 in the next twelve months. This suggests a possible upside of 47.3% from the stock's current price. View analysts price targets for TARS or view top-rated stocks among Wall Street analysts .

How have TARS shares performed in 2024?

Tarsus Pharmaceuticals' stock was trading at $20.25 at the beginning of 2024. Since then, TARS stock has increased by 62.2% and is now trading at $32.85. View the best growth stocks for 2024 here .

When is Tarsus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our TARS earnings forecast .

How were Tarsus Pharmaceuticals' earnings last quarter?

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) issued its quarterly earnings results on Tuesday, February, 27th. The company reported ($1.31) earnings per share for the quarter, beating analysts' consensus estimates of ($1.37) by $0.06. The business had revenue of $13.08 million for the quarter, compared to analysts' expectations of $4.63 million. During the same period in the previous year, the business earned ($0.49) earnings per share.

What ETFs hold Tarsus Pharmaceuticals' stock?

ETFs with the largest weight of Tarsus Pharmaceuticals (NASDAQ:TARS) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP) , SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) . ALPS Medical Breakthroughs ETF (SBIO) .

When did Tarsus Pharmaceuticals IPO?

Tarsus Pharmaceuticals (TARS) raised $80 million in an initial public offering on Friday, October 16th 2020. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Jefferies and Raymond James acted as the underwriters for the IPO and LifeSci Capital and Ladenburg Thalmann were co-managers.

Who are Tarsus Pharmaceuticals' major shareholders?

Tarsus Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.56%). Insiders that own company stock include Andrew D Goldberg, Aziz Mottiwala , Bobak R Azamian, Bobak R Azamian , Bryan Wahl, Dianne C Whitfield, Elizabeth Yeu Lin, Jose M Trevejo, Leonard M Greenstein, Mark J Holdbrook, Michael Ackermann , Rtw Investments, Lp, Seshadri Neervannan and Vivo Capital Ix, Llc. View institutional ownership trends .

How do I buy shares of Tarsus Pharmaceuticals?

Shares of TARS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:TARS

Tarsus Pharmaceuticals (TARS) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free TARS Stock Alerts

$32.85

-1.57 (-4.56%)

(As of 04/18/2024 ET)

Compare

Today's Range: $32.81
▼
$34.55
50-Day Range: $29.43
▼
$39.22
52-Week Range: $12.57
▼
$40.40

Volume: 317,820 shs
Average Volume: 745,504 shs
Market Capitalization: $1.12 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $48.38

Get Tarsus Pharmaceuticals alerts:

Tarsus Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.88 Rating Score
Upside/Downside: 47.3% Upside
$48.38 Price Target
Short Interest: Bearish
22.94% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.67
Based on 4 Articles This Week
Insider Trading: Selling Shares
$749,578 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($4.55) to ($2.62) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.96 out of 5 stars

Medical Sector

356th out of 919 stocks

Biological Products, Except Diagnostic Industry

52nd out of 151 stocks

4.4

Analyst's Opinion

Consensus Rating
Tarsus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Tarsus Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

0.0

Short Interest

Percentage of Shares Shorted
22.94% of the outstanding shares of Tarsus Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Tarsus Pharmaceuticals has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.
Change versus previous month
Short interest in Tarsus Pharmaceuticals has recently increased by 9.03%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Tarsus Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Tarsus Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TARS.

3.2

News and Social Media Coverage

News Sentiment
Tarsus Pharmaceuticals has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Tarsus Pharmaceuticals this week, compared to 3 articles on an average week.
Search Interest
5 people have searched for TARS on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added Tarsus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -56% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Tarsus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $749,578.00 in company stock.
Percentage Held by Insiders
11.54% of the stock of Tarsus Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
90.01% of the stock of Tarsus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Tarsus Pharmaceuticals are expected to grow in the coming year, from ($4.55) to ($2.62) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Tarsus Pharmaceuticals is -7.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Tarsus Pharmaceuticals is -7.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Tarsus Pharmaceuticals has a P/B Ratio of 5.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Tarsus Pharmaceuticals Stock (NASDAQ:TARS)

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

TARS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TARS Stock News Headlines

March 20, 2024 | insidertrades.com

Bryan Wahl Sells 4,436 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stock

April 18, 2024 | americanbankingnews.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Rating of "Moderate Buy" from Brokerages

April 18, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

April 14, 2024 | americanbankingnews.com

Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Down 5.2%

April 8, 2024 | finance.yahoo.com

Wall Street Analysts Predict a 47.12% Upside in Tarsus Pharmaceuticals (TARS): Here's What You Should Know

April 6, 2024 | msn.com

Scientists share trial results for new tick-repelling drug for humans: 'An amazing opportunity'

March 21, 2024 | investing.com

Tarsus Pharmaceuticals executive sells over $130k in company stock

March 21, 2024 | investing.com

Tarsus Pharmaceuticals exec sells over $135k in stock

April 18, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

March 18, 2024 | msn.com

Pill Targeting Tick-Induced Lyme Disease Shows Promise in Human Trials

March 16, 2024 | finance.yahoo.com

TARS Apr 2024 25.000 call

March 16, 2024 | finance.yahoo.com

TARS Apr 2024 17.500 put

March 16, 2024 | finance.yahoo.com

TARS Apr 2024 12.500 call

March 13, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: ProQR (PRQR) and Crinetics Pharmaceuticals (CRNX)

March 5, 2024 | globenewswire.com

Tarsus to Participate at Upcoming Investor Conferences

March 5, 2024 | globenewswire.com

Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis

March 2, 2024 | investing.com

Tarsus Pharmaceuticals launches $100 million stock offering

March 1, 2024 | finance.yahoo.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates

March 1, 2024 | msn.com

Tarsus Pharmaceuticals stock dips after pricing $100M securities offering

March 1, 2024 | marketwatch.com

Tarsus Pharmaceuticals Shares Slip Premarket After Stock Offering

March 1, 2024 | globenewswire.com

Tarsus Announces Pricing of $100.0 Million Public Offering

February 29, 2024 | seekingalpha.com

Tarsus Pharmaceuticals, Inc. (TARS) Q4 2023 Earnings Call Transcript

February 29, 2024 | marketwatch.com

Tarsus Pharmaceuticals Shares Fall 11% After Public Offering News

February 29, 2024 | msn.com

Tarsus announces proposed $100M public offering

February 29, 2024 | globenewswire.com

Tarsus Announces Proposed $100.0 Million Public Offering

February 29, 2024 | finance.yahoo.com

Party Time: Brokers Just Made Major Increases To Their Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Earnings Forecasts

February 28, 2024 | markets.businessinsider.com

Buy Rating Affirmed: Tarsus Pharmaceuticals’ Strong Q4 and Robust Pipeline Fuel Upward Price Revision

See More Headlines

Receive TARS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tarsus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/27/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:TARS
CUSIP: N/A
CIK: 1819790
Web: www.tarsusrx.com
Phone: 949-409-9820
Fax: N/A
Employees: 244
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $48.38
High Stock Price Target: $59.00
Low Stock Price Target: $30.00
Potential Upside/Downside: +47.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.88
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.64)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-135,890,000.00
Net Margins: N/A
Pretax Margin: -778.89%
Return on Equity: -74.28%
Return on Assets: -58.20%

Debt

Debt-to-Equity Ratio: 0.15
Current Ratio: 6.93
Quick Ratio: 6.85

Sales & Book Value

Annual Sales: $17.45 million
Price / Sales: 64.42
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.95 per share
Price / Book: 5.52

Miscellaneous

Outstanding Shares: 34,220,000
Free Float: 30,270,000
Market Cap: $1.12 billion
Optionable: Optionable
Beta: 1.05

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Dr. Bobak R. Azamian M.D.
Co-Founder, President, CEO & Chairman
Dr. Bryan Wahl J.D. (Age 46)
M.D., General Counsel & Corporate Secretary
Comp: $619.09k
Dr. Elizabeth Yeu Lin M.D. (Age 46)
Chief Medical Advisor & Director
Comp: $286k
Mr. Jeffrey S. Farrow (Age 62)
CFO & Chief Strategy Officer
Dr. Seshadri Neervannan Ph.D. (Age 56)
Chief Operating Officer
Comp: $486.67k
Mr. David Nakasone
Head of Investor Relations
Ms. Adrienne Kemp
Senior Director of Corporate Communications
Mr. Matthew Rossen M.B.A. (Age 46)
Vice President of Marketing
Mr. Scott Youmans
Vice President of Sales
Ms. Dianne C. Whitfield M.S.W. (Age 47)
Chief Human Resources Officer
Comp: $578.9k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TARS Stock Analysis - Frequently Asked Questions

Should I buy or sell Tarsus Pharmaceuticals stock right now?: 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tarsus Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TARS shares.
View TARS analyst ratings or view top-rated stocks.
What is Tarsus Pharmaceuticals' stock price target for 2024?: 8 Wall Street analysts have issued 1 year price objectives for Tarsus Pharmaceuticals' stock. Their TARS share price targets range from $30.00 to $59.00. On average, they anticipate the company's share price to reach $48.38 in the next twelve months. This suggests a possible upside of 47.3% from the stock's current price.
View analysts price targets for TARS or view top-rated stocks among Wall Street analysts.
How have TARS shares performed in 2024?: Tarsus Pharmaceuticals' stock was trading at $20.25 at the beginning of 2024. Since then, TARS stock has increased by 62.2% and is now trading at $32.85.
View the best growth stocks for 2024 here.
When is Tarsus Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our TARS earnings forecast.
How were Tarsus Pharmaceuticals' earnings last quarter?: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) issued its quarterly earnings results on Tuesday, February, 27th. The company reported ($1.31) earnings per share for the quarter, beating analysts' consensus estimates of ($1.37) by $0.06. The business had revenue of $13.08 million for the quarter, compared to analysts' expectations of $4.63 million. During the same period in the previous year, the business earned ($0.49) earnings per share.

What ETFs hold Tarsus Pharmaceuticals' stock?: ETFs with the largest weight of Tarsus Pharmaceuticals (NASDAQ:TARS) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).ALPS Medical Breakthroughs ETF (SBIO).
When did Tarsus Pharmaceuticals IPO?: Tarsus Pharmaceuticals (TARS) raised $80 million in an initial public offering on Friday, October 16th 2020. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Jefferies and Raymond James acted as the underwriters for the IPO and LifeSci Capital and Ladenburg Thalmann were co-managers.
Who are Tarsus Pharmaceuticals' major shareholders?: Tarsus Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.56%). Insiders that own company stock include Andrew D Goldberg, Aziz Mottiwala, Bobak R Azamian, Bobak R Azamian, Bryan Wahl, Dianne C Whitfield, Elizabeth Yeu Lin, Jose M Trevejo, Leonard M Greenstein, Mark J Holdbrook, Michael Ackermann, Rtw Investments, Lp, Seshadri Neervannan and Vivo Capital Ix, Llc.
View institutional ownership trends.
How do I buy shares of Tarsus Pharmaceuticals?: Shares of TARS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TARS) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Tarsus Pharmaceuticals (TARS) Stock Price, News & Analysis

Tarsus Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Tarsus Pharmaceuticals Stock (NASDAQ:TARS)

TARS Stock Price History

TARS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

TARS Stock Analysis - Frequently Asked Questions

Overall MarketRank^™